SCHEMBL12150473

SCHEMBL12150473

CP(C)(=O)CO[C@H]1O[C@@H](n2cnc(C(N)=O)n2)[C@H](O)[C@@H]1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ ADORA1 P30542 2/20 0.58
▸ ALDH1A1 P00352 2/20 0.58
▸ TSHR P16473 2/20 0.58
▸ GLA P06280 1/20 0.58
▸ EIF4E P06730 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ TOP1 P11387 1/20 0.58
▸ THPO P40225 1/20 0.58
▸ PMP22 Q01453 1/20 0.58
▸ PNP P00491 3/20 0.46
▸ TMEM97 Q5BJF2 2/20 0.40
▸ HTR2C P28335 1/20 0.40
▸ HTR2B P41595 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ ATIC P31939 2/20 0.34
▸ FBP1 P09467 1/20 0.34
▸ ADRB3 P13945 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12150504 0.90 PNP (0.59) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL12149570 0.82 LMNA (0.63) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL16199367 0.82 LMNA (0.60) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL12300345 0.81 LMNA (0.72) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL12151511 0.80 LMNA (0.34) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL14010400 0.78 LMNA (0.39) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL12150468 0.77 LMNA (0.38) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL20277606 0.77 LMNA (0.66) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL20277543 0.77 LMNA (0.66) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL12300549 0.76 LMNA (0.58) LMNASMN1; SMN2ADORA1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871785-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2014-10-28 — — US disclosed
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. (US) 2011-11-24 — — US disclosed
US-7452901-B2 Anti-cancer phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-11-18 — — US disclosed
US-7429565-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP LMNA 2918/4885SMN1; SMN2 2517/4885ADORA1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback